(Q38494659)

3 September 2017

1 reference

title

Minimal residual disease in acute myeloid leukemia--current status and future perspectives (English)

1 reference

3 September 2017

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25994952%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

author name string

Sabine Kayser

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25994952%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Wendy Stock

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25994952%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Richard F Schlenk

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25994952%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

publication date

1 June 2015

1 reference

Current hematologic malignancy reports

3 September 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25994952%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25994952%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25994952%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

page(s)

132-144

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25994952%20AND%20SRC:MED&resulttype=core&format=json

Therapeutic advances in acute myeloid leukemia

12 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0260-7

Acute myeloid leukaemia in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0260-7

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0260-7

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0260-7

Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for "prime time"?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0260-7

Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0260-7

Post-remission therapy for acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0260-7

High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0260-7

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0260-7

Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0260-7

Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0260-7

Has MRD monitoring superseded other prognostic factors in adult ALL?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0260-7

Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0260-7

Statistical evaluation of surrogate endpoints with examples from cancer clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0260-7

Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0260-7

A deep profiler's guide to cytometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0260-7

viSNE enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0260-7

Defining consensus leukemia-associated immunophenotypes for detection of minimal residual disease in acute myeloid leukemia in a multicenter setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0260-7

Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0260-7

Immunophenotypic differences between diagnosis and relapse in childhood AML: Implications for MRD monitoring.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0260-7

The real-time polymerase chain reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0260-7

Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0260-7

Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0260-7

Development of standardized approaches to reporting of minimal residual disease data using a reporting software package designed within the European LeukemiaNet.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0260-7

Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0260-7

Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0260-7

Can we say farewell to monitoring minimal residual disease in acute promyelocytic leukaemia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0260-7

Retinoic acid and arsenic trioxide for acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0260-7

MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0260-7

Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0260-7

Core binding factor acute myeloid leukemia: the impact of age, leukocyte count, molecular findings, and minimal residual disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0260-7

Prognostic value of real-time quantitative PCR (RQ-PCR) in AML with t(8;21).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0260-7

The quality of molecular response to chemotherapy is predictive for the outcome of AML1-ETO-positive AML and is independent of pretreatment risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0260-7

Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0260-7

KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0260-7

Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0260-7

Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0260-7

Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0260-7

The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0260-7

Anthracycline dose intensification improves molecular response and outcome of patients treated for core binding factor acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0260-7

Prognostic impact of minimal residual disease in CBFB-MYH11-positive acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0260-7

New score predicting for prognosis in PML-RARA+, AML1-ETO+, or CBFBMYH11+ acute myeloid leukemia based on quantification of fusion transcripts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0260-7

Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0260-7

Cytogenetic abnormalities in childhood acute myeloid leukaemia: a Nordic series comprising all children enrolled in the NOPHO-93-AML trial between 1993 and 2001.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0260-7

Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0260-7

Prognostic factors in adult patients up to 60 years old with acute myeloid leukemia and translocations of chromosome band 11q23: individual patient data-based meta-analysis of the German Acute Myeloid Leukemia Intergroup

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0260-7

Development of a real‐time RT‐PCR assay for the quantification of the most frequent MLL/AF9 fusion types resulting from translocation t(9;11)(p22;q23) in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0260-7

A novel RT-qPCR assay for quantification of the MLL-MLLT3 fusion transcript in acute myeloid leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0260-7

Acute myeloid leukemia with mutated NPM1: diagnosis, prognosis and therapeutic perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0260-7

Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0260-7

Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0260-7

Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0260-7

Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0260-7

Molecular response assessment by quantitative real-time polymerase chain reaction after induction therapy in NPM1-mutated patients identifies those at high risk of relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0260-7

The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0260-7

FLT3 tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0260-7

FLT3 length mutations as marker for follow-up studies in acute myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0260-7

Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibit

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0260-7

FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0260-7

Improved FLT3 internal tandem duplication PCR assay predicts outcome after allogeneic transplant for acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0260-7

Tandem duplication PCR: an ultrasensitive assay for the detection of internal tandem duplications of the FLT3 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0260-7

The $1,000 genome, the $100,000 analysis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0260-7

DNMT3A Mutations in Acute Myeloid Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0260-7

Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0260-7

Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0260-7

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0260-7

Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0260-7

Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0260-7

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0260-7

DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0260-7

WT1 monitoring in core binding factor AML: comparison with specific chimeric products

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0260-7

Usefulness of quantitative assessment of the WT1 gene transcript as a marker for minimal residual disease detection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0260-7

Early prediction of treatment outcome in acute myeloid leukemia by measurement of WT1 transcript levels in peripheral blood samples collected after chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0260-7

Wilms' tumor gene 1 expression analysis by real-time quantitative polymerase chain reaction for monitoring of minimal residual disease in acute leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0260-7

Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0260-7

Minimal residual disease-directed preemptive treatment with azacitidine in patients with NPM1-mutant acute myeloid leukemia and molecular relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0260-7

Donor lymphocyte infusion induces polyspecific CD8(+) T-cell responses with concurrent molecular remission in acute myeloid leukemia with NPM1 mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0260-7

Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0260-7

A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0260-7

Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0260-7

Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0260-7

Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0260-7

High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0260-7

Persistence ofDNMT3Amutations at long-term remission in adult patients with AML

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-015-0260-7

Patient-specific analysis of FLT3 internal tandem duplications for the prognostication and monitoring of acute myeloid leukemia

21 January 2018

1 reference

12 December 2020

Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia: a comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse

1 reference

12 December 2020

Using quantification of the PML-RARalpha transcript to stratify the risk of relapse in patients with acute promyelocytic leukemia

1 reference

12 December 2020

Next-generation sequencing for minimal residual disease monitoring in acute myeloid leukemia patients with FLT3-ITD or NPM1 mutations

1 reference

12 December 2020

Mutated regions of nucleophosmin 1 elicit both CD4(+) and CD8(+) T-cell responses in patients with acute myeloid leukemia

1 reference

12 December 2020

Stability of leukemia-associated aberrant immunophenotypes in patients with acute myeloid leukemia between diagnosis and relapse: comparison with cytomorphologic, cytogenetic, and molecular genetic findings

1 reference

12 December 2020

Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples

1 reference

12 December 2020

Clinical implications of minimal residual disease monitoring by quantitative polymerase chain reaction in acute myeloid leukemia patients bearing nucleophosmin (NPM1) mutations

1 reference

12 December 2020

1 reference

12 December 2020

A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML Intergroup

1 reference

12 December 2020

Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification

1 reference

12 December 2020

Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial

1 reference

12 December 2020

Prognostic impact of minimal residual disease analysis by flow cytometry in patients with acute myeloid leukemia before and after allogeneic hemopoietic stem cell transplantation

1 reference

12 December 2020

MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin

1 reference

12 December 2020

NPM1 mutations are more stable than FLT3 mutations during the course of disease in patients with acute myeloid leukemia

1 reference

12 December 2020

Fifty-one patients with acute myeloid leukemia and translocation t(8;21)(q22;q22): an additional deletion in 9q is an adverse prognostic factor.

1 reference

12 December 2020

The prognostic value of MLL-AF9 detection in patients with t(9;11)(p22;q23)-positive acute myeloid leukemia

1 reference

12 December 2020